Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex (NASDAQ:GNPX) reported positive preclinical data for its diabetes gene therapy candidate Pdx1/MafA (PM, GPX-002) in Type 2 diabetes mouse models, presented at the 2026 ASGCT Annual Meeting.
Pancreatic AAV-Pdx1/MafA delivery reversed hyperglycemia within four weeks and improved β-cell function, insulin secretion, and maturation markers in high-fat-diet mice.
Genprex (NASDAQ: GNPX) announced that the Israel Patent Office granted a patent covering the use of Reqorsa® (quaratusugene ozeplasmid) in combination with PD-1 antibodies to treat cancer.
The patent expands protection for Reqorsa® in Israel and complements previously granted combination patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe. Reqorsa is being developed initially in combination with approved cancer drugs for lung cancer and has shown complementary activity with targeted drugs and immunotherapies in preclinical studies.
Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data showing the Pdx1/MafA (PM, GPX-002) gene therapy reversed HFD-induced hyperglycemia in Type 2 diabetic mouse models with complete rescue by four weeks after intrapancreatic AAV-8 delivery. CMV and RIP promoter constructs improved ex-vivo glucose-stimulated insulin secretion to levels similar to regular-diet controls. Electron microscopy showed more mature insulin granules and transcriptomic analysis indicated β-cell maturation. The poster (ASGCT 2026, Abstract 2419) is scheduled for May 13, 2026; the team notes technical translatability to humans via endoscopic retrograde cholangiopancreatography.
Genprex (NASDAQ:GNPX) announced that a research collaborator's abstract reporting positive clinical biomarker data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) was selected for publication at the 2026 ASCO Annual Meeting, May 29–June 2, 2026 in Chicago.
The abstract (e15184) describes predictive biomarkers for progression‑free survival (PFS) in patients receiving Reqorsa, which the company says may help enrich lung cancer trials and predict patient response.
Genprex (NASDAQ: GNPX) signed a Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN biomarkers that may predict response to REQORSA (quaratusugene ozeplasmid) gene therapy for NSCLC and SCLC. Research aims to refine patient selection for Acclaim-1 and Acclaim-3 trials and optimize outcomes.
Acclaim-1 (REQORSA + Tagrisso) completed Phase 1 dose escalation with no dose-limiting toxicities and showed early efficacy, including three of 12 patients with prolonged PFS and one patient with a partial response maintained through ~42 months. Acclaim-3 (REQORSA + Tecentriq) moved to Phase 2 after a Phase 1 with no DLTs and one unconfirmed partial remission.
Genprex (NASDAQ: GNPX) collaborators presented positive preclinical data for Reqorsa (quaratusugene ozeplasmid) at AACR 2026 (April 17-22). Studies showed 79% tumor shrinkage with Quar Oze plus alectinib in an ALK+ sensitive model (p=0.0135) and synergistic tumor reduction and survival benefit in an alectinib-resistant model (p=0.0001).
Additional findings: TROP2 low/PTEN high associated with primary resistance; Quar Oze restored NK cell activity, producing complete tumor regression in preclinical cohorts (up to 67%). All data are preclinical.
Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data for Reqorsa (quaratusugene ozeplasmid) at the AACR Annual Meeting, April 17-22, 2026.
Key findings: Quar Oze induced up to 79% tumor shrinkage in ALK+ models (p=0.0135), synergized with alectinib (p=0.0001), drove complete regressions in mice (67% Tusc2 KO, 33% WT), and identified TROP2 low/PTEN high as potential resistance biomarkers.
Genprex (NASDAQ: GNPX) announced that its executive leadership will attend BIO Europe Spring in Lisbon, Portugal, March 23-25, 2026. Attendees include Ryan Confer, President and CEO, and Thomas Gallagher, SVP of Intellectual Property and Licensing.
Genprex said executives will be available for one-on-one meetings to provide overviews of the company’s gene therapy programs for cancer and diabetes; meeting requests can be made via the conference portal or investors@genprex.com.
Genprex (NASDAQ:GNPX) announced that the Japanese Patent Office issued a favorable appeal decision to grant a patent for REQORSA in combination with PD-L1 antibodies, and the European Patent Office issued a decision to grant a patent for REQORSA with PD-1 antibodies.
Genprex maintains exclusive licenses and says these patents strengthen protection for therapeutic combinations, including the Acclaim-3 small cell lung cancer trial combining REQORSA with PD-L1 antibodies. The company already holds related U.S. and Korea patents, and other international grants and pendings.
Genprex (NASDAQ: GNPX) announced IP Australia issued a Notice of Acceptance on Feb 5, 2026, for a patent application claiming use of Reqorsa® gene therapy combined with PD-L1 antibodies to treat cancers.
The company notes related patents are already granted in the U.S. and Korea and says the patent, if granted, will strengthen exclusivity in Australia while it advances the Acclaim-3 clinical trial and opens an additional site at the University of Kentucky.